#MethodologyMonday
#MethodologyMonday
How the Rare Disease community is leading the way in Trial Design -

At #RareResearch25, Prof Jeffrey Krischer shares how innovative clinical trial designs are opening up new options for rare disease research.

▶️ Watch his keynote: www.youtube.com/watc...
Clinical Trial Designs - New Options for the Study of Rare Diseases: J Krischer
Professor Jeffrey Krischer, University of South Florida, USA
www.youtube.com
June 30, 2025 at 1:37 PM
#MethodologyMonday: From Research To Delivery

How does basic science become a clinical therapy for rare diseases? Prof Marc Humbert explains how collaboration leads to positive outcomes.

▶️ Listen how we translate science into meaningful therapies: www.youtube.com/watc...
Translating Basic Science into Meaningful Therapies: M Humbert
Professor Marc Humbert, Université Paris-Saclay
www.youtube.com
June 23, 2025 at 8:42 AM
#MethodologyMonday: Platform Trials

What if one trial could answer many research questions at once? Dr Leanne Hays explains benefits of Platform Trials and how they can make trials faster and more efficient.

🎥 From our Rare Disease Research Conference: youtu.be/pNjA5miOlK0...
Trial Methodology - Platform Trials: L Hays
Dr Leanne Hays, HRB PRIME Ireland, Irish Critical Care-CTN
youtu.be
June 16, 2025 at 11:04 AM
#MethodologyMonday: Study Within A Trial (SWAT)

How do we reduce uncertainty in clinical trials and make future ones better? Prof Valerie Smith unpacks the value of SWATs and how they strengthen trial design.

🎥 From our Rare Disease Research Conference: youtu.be/ARKEeo8nVHw...
Trial Methodology - Study Within a Trial (SWAT): V Smith
Professor Valerie Smith, UCD
youtu.be
June 9, 2025 at 9:10 AM
Shariq et al's scoping review on barriers & facilitators in the recruitment of people with a disability draws on 5 themes
Risk v benefit
Design & management of recruitment protocol
Internal & external validity
Consent & ethics
Systemic factors
#MethodologyMonday
pmc.ncbi.nlm.nih.gov/articles/PMC...
Barriers and facilitators to the recruitment of disabled people to clinical trials: a scoping review
Underrepresentation of disabled groups in clinical trials results in an inadequate evidence base for their clinical care, which drives health inequalities. This study aims to review and map the potential barriers and facilitators to the recruitment ...
pmc.ncbi.nlm.nih.gov
January 12, 2026 at 9:03 AM
Next up #MethodologyMonday focuses on pregnant women. Sewell et al summarise the scientific, ethical, & legal considerations governing research conducted during pregnancy. They also recommend strategies for overcoming impediments to inclusion and trial conduct.

pubmed.ncbi.nlm.nih.gov/35934117/
Scientific, ethical, and legal considerations for the inclusion of pregnant people in clinical trials - PubMed
Clinical trials to address the COVID-19 public health emergency have broadly excluded pregnant people from participation, illustrating a long-standing trend of clinical trial exclusion that has led to a clear knowledge gap and unmet need in the treatment and prevention of medical conditions experien …
pubmed.ncbi.nlm.nih.gov
December 22, 2025 at 8:40 AM
The authors analyse the inclusion of women in cardiovascular trials in #MethodologyMonday. Underrepresentation remains a persistent issue & increasingly so for minority women. The current situation has been shown to lead to > side effects & potentially worse outcomes
doi: 10.1016/j.ahjo.2022.100109
December 8, 2025 at 10:10 AM
This #MethodologyMonday by Mohan & Freedman on persistent under-representation of racial & ethnic minorities in clinical trials. They argue that pursuing representative enrollment throughout clinical development is not only a matter of equity but also of scientific rigour.

doi.org/10.1002/cpt....
A Review of the Evolving Landscape of Inclusive Research and Improved Clinical Trial Access
Current clinical research does not reflect the diversity of patient populations, despite continued recommendations to increase enrollment of under-represented racial and ethnic groups. The ramificati...
doi.org
November 17, 2025 at 2:26 PM
This #MethodologyMonday by Booth et al focuses on case studies from three NIHR-funded trials demonstrating how publicly available UK population datasets can be used to identify under-served communities. They reflect on the challenges and future developments.

pmc.ncbi.nlm.nih.gov/articles/PMC...
Using publicly available UK datasets to identify recruitment sites to maximise inclusion of under-served groups: three case studies
There is strong evidence that those recruited into studies are not always representative of the population for whom the research is most relevant. Development of the study design and funding decisions are points in the research process where ...
pmc.ncbi.nlm.nih.gov
November 3, 2025 at 3:50 PM
A #MethodologyMonday - Raven-Gregg & Shepherd on how methodology studies on attitudes to deferred consent often poorly represent ethnic minority groups. They argue for more equitable research, we need better reporting & greater diversity in research teams & ethics committees.
doi.org/10.1186/s130...
Exploring the inclusion of under-served groups in trials methodology research: an example from ethnic minority populations’ views on deferred consent - Trials
Background Deferred consent is used to recruit patients in emergency research, when informed consent cannot be obtained prior to enrolment. This model of consent allows studies to recruit larger numbe...
doi.org
October 20, 2025 at 7:46 AM
An audit at a UK primary care CTU assessed the inclusion of underserved groups in trials in this #MethodologyMonday.
The authors conclude that many explicit exclusions may not be strictly necessary & call for more inclusive eligibility criteria & standardised data collection
doi.org/10.1186/s130...
Inclusion of under-served groups in trials: an audit at a UK primary care clinical trials unit - Trials
Background Clinical trials need to include patients who are representative of the population who may receive the tested interventions in the future. The importance of inclusivity is recognised by ethical and funding bodies and has public support. Appropriate inclusion is required to provide equitable evidence-based healthcare and to comply with ethical principles for research. However, there is little information about the inclusivity of most under-served groups in UK clinical trials. Methods This audit assesses the inclusion of under-served groups in trials run by the Oxford Primary Care Clinical Trials Unit (PC-CTU). We included trials with ethical approval between 2017 and 2023. We checked protocols, patient-facing information and selected data collection tools for information on the under-served groups in the INCLUDE guidance and protected characteristics in the UK Equality Act 2010, to identify explicit exclusions and data collection. Results We included 19 trials. They were in a variety of clinical conditions, testing different types of interventions, both Clinical Trial of an Investigational Medicinal Product (CTIMP) and non-CTIMP. Most were non-commercially funded. We reviewed 21 protocols, 29 Patient Information Sheets/Leaflets and 40 data collection tools. Common exclusions were based on age (19), sex or gender (11), language (8), capacity to consent (14), pregnancy (11), multiple health conditions (10) and severity of illness (17). Trials most often collected data on age (19), sex or gender (15), ethnicity (16), education (11), address (13), mental health conditions (6), who gave consent (19), addiction (6), multiple health conditions (10), severity of illness (17), smoking status (12) and obesity (13). Conclusions Often, exclusions were due to the focusing of the trial for a specific group, such as older people, women, or people being treated for a specific severity of condition. However, many explicit exclusions may not have been essential, may have reduced the inclusivity of the trials and might limit the applicability of the trial’s findings to people to whom the tested interventions might be relevant. These include the exclusion of people aged under 18, people without English language fluency and people without capacity to consent. All trials could have collected more informative data on under-served group status.
doi.org
October 13, 2025 at 1:10 PM
Oct #MethodologyMonday focuses on a recent editorial: the usefulness of trial data depends crucially on transparent, consistent reporting of who was actually enrolled, not could have been. Trials will introduce a requirement to address this (01/2026).
trialsjournal.biomedcentral.com/articles/10....
Who is in your trial? Improving the reporting of participant characteristics in trial protocols and results - Trials
Advertisement
trialsjournal.biomedcentral.com
October 6, 2025 at 12:01 PM
The last September #MethodologyMonday includes input from the consortium on improving the inclusion of those with impaired capacity with the dedicated INCLUDE framework. This article outlines the development of this dedicated framework.

trialsjournal.biomedcentral.com/articles/10....
September 29, 2025 at 7:07 AM
In the mixed-methods systematic review carried out by Stokes et al, not only were barriers identified, but also facilitators for the implementation of capacity legislation in care homes.

#MethodologyMonday
pubmed.ncbi.nlm.nih.gov/40370080/
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
September 22, 2025 at 8:22 AM
Gréaux et al identified barriers across the health system (cost, training, coordinated service) and wider contributing factors (social stigma or health literacy). Moreover, the solutions proposed dont necessarily address these needs
#MethodologyMonday
equityhealthj.biomedcentral.com/articles/10....
September 15, 2025 at 1:04 PM
Bishop et al discuss inclusion of adults with intellectual disabilities in #MethodologyMonday.

Findings: non-accessible research design, lack of confidence with capacity & consent, limited resources, & the need for training.

onlinelibrary.wiley.com/doi/10.1111/...
The inclusion of adults with intellectual disabilities in health research – challenges, barriers and opportunities: a mixed‐method study among stakeholders in England
Background The study aims to understand system barriers to research participation for people with intellectual disabilities. Methods A mixed-methods approach examined the inclusivity of people wit...
onlinelibrary.wiley.com
September 8, 2025 at 9:08 AM
September #MethodologyMonday will focus on the inclusion of persons with disabilities. First, a call to action from Anderson and colleagues for disability inclusion in health research.

(not open access)
www.nature.com/articles/s41...
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
September 1, 2025 at 1:16 PM
In this week's #MethodologyMonday post, Rubagumya et al explore the impact of enrolling patients from lower middle-income countries on the bibliometric output. While many trials include such publics it is not reflected in their bibliometric output.

jamanetwork.com/journals/jam...
Participation of Lower and Upper Middle–Income Countries in Oncology Clinical Trials
This cross-sectional study examines the inclusion of patients with cancer from lower and upper middle–income countries in randomized clinical trials conducted by high-income countries.
jamanetwork.com
August 11, 2025 at 9:48 AM
The Digital Cancer Research and Vocal co-developed this week’s #MethodologyMonday guidance with patients. They came up with 5 principles for the development of technology clinical trials and an accompanying checklist.

christie.openrepository.com/bitstream/ha...
christie.openrepository.com
July 21, 2025 at 6:47 AM
In this hashtag#MethodologyMonday, Chokkara et al. look at the recruitment of underrepresented populations in COVID-19 studies conducted in the US and found: they exclude people with high-risk chronic conditions & trials excluded children, pregnant & lactating women
link.springer.com/article/10.1...
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
July 7, 2025 at 8:20 AM
#MethodologyMonday: a call to action from Reza and colleagues for the inclusion of all populations impacted by heart failure with reduced ejection fraction in clinical trials. They also catalogue barriers & propose strategies to ⬆️ inclusivity in future trials.

academic.oup.com/eurheartjsup...
Representation matters: a call for inclusivity and equity in heart failure clinical trials
Abstract. The burden of heart failure remains substantial worldwide, and heart failure with reduced ejection fraction (HFrEF) affects approximately half of
academic.oup.com
June 30, 2025 at 8:54 AM
Daho et al demonstrate through a systematic review of European cancer trials, that a large majority exclude populations with psychiatric & neurological disorders. Often citing compliance concerns & understanding of informed consent.
#MethodologyMonday
onlinelibrary.wiley.com/doi/full/10....
Exploring Barriers to Inclusivity: Systematic Analysis of Exclusion Criteria and Potential Bias in Clinical Cancer Trials for Psychiatric and Neurological Conditions in European Protocols
Background Cancer clinical trials often employ exclusion criteria that can impact vulnerable populations, particularly individuals with psychological, psychiatric, or neurological conditions. Aims...
onlinelibrary.wiley.com
June 23, 2025 at 2:14 PM
For #MethodologyMonday, we revisit the impact of exclusion criteria on sex and race. Stanton et al investigated the potential impact that common exclusion criteria by race and sex have on trial eligibility of patients with ischemic stroke.

www.ahajournals.org/doi/full/10....
Clinical Trial Exclusion Criteria Affect Trial Inclusivity by Race and Sex | Journal of the American Heart Association
www.ahajournals.org
June 16, 2025 at 8:12 AM
Another #MethodologyMonday on DCTs. Khozin & Coravos highlight the considerations to ensure that decentralised aspects lead to safe & valid research: data protection & cybersecurity, but also limitations linked to technical validation of tools & their durability
www.researchgate.net/publication/...
(PDF) Decentralized Trials in the Age of Real‐World Evidence and Inclusivity in Clinical Investigations
PDF | On Apr 23, 2019, Sean Khozin and others published Decentralized Trials in the Age of Real‐World Evidence and Inclusivity in Clinical Investigations | Find, read and cite all the research you nee...
www.researchgate.net
June 10, 2025 at 7:24 AM
How is diversity integrated into decentralised clinical trials? The authors list 2 key areas linked to participant selection that should be prioritised for #MethodologyMonday.

Diversity in decentralized clinical trials: prioritizing inclusion of underrepresented groups. doi.org/10.1186/s129...
Diversity in decentralized clinical trials: prioritizing inclusion of underrepresented groups - BMC Medical Ethics
Background The importance of more diversity of study populations in clinical trials is currently widely acknowledged. Decentralized clinical trial (DCT) approaches are presented as a potential means to broaden diversity by eliminating several barriers to participation. However, the precise meaning of, and objectives related to diversity in DCTs remain unclear. Diversity runs the risk of becoming a ‘buzzword’: widely acknowledged to be important, yet prone to multiple interpretations and challenging to implement in practice. We argue that the aim of increasing diversity in clinical trials requires clear and well-substantiated specifications. Methods We analyze the concept of diversity and the ethical requirements surrounding fair participant selection within the context of clinical research, in order to further specify and operationalize the aim of increasing diversity in the context of DCTs. Results Through analyzing the concept of diversity and ethical requirements for fair participant selection, we propose that diversity should be specified in a way that improves the position of the groups that are currently most underrepresented in the research context. In practice, this entails that, in order to contribute to diversity, the selection of participants should prioritize (i) gaining scientific knowledge on groups for which this is lacking, and (ii) inclusion of underrepresented groups in research when appropriate considering a study’s objectives, and risks and benefits. Conclusions Our analysis facilitates translating the aim of increasing diversity with DCTs to more specific and actionable objectives for recruitment and inclusion. Moreover, it contributes to a further specification of the concept of diversity and fair participant selection in research contexts.
doi.org
June 2, 2025 at 11:49 AM